Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NUTEX InvestmentsBUD:NUTEX 18 Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus rates BUD:NUTEX with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 692 Drug Manufacturers companies, NUTEX Investments ranks worse than 144508.53% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for NUTEX Investments's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of NUTEX Investments was 8.17. The lowest was -1302.75. And the median was -647.29.
BUD:NUTEX's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.68 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
NUTEX Investments Debt-to-EBITDA Related Terms
NUTEX Investments Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
NUTEX Investments (BUD:NUTEX) has a Debt-to-EBITDA of 0.00 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NUTEX Investments. According to the industry distribution chart, NUTEX Investments ranks #999999 out of 692 companies in the Drug Manufacturers industry.
Is NUTEX Investments' Debt-to-EBITDA too high?
NUTEX Investments' current Debt-to-EBITDA is 0.00. Based on the distribution chart, NUTEX Investments ranks #999999 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, NUTEX Investments has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #999999 out of 692 companies for Debt-to-EBITDA. This places NUTEX Investments in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NUTEX Investments. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
NUTEX Investments (BUD:NUTEX) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. NUTEX Investments' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
18GF Score
Get the complete analysis for BUD:NUTEX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
